4 Result(s)

Article

Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation

The BCR-ABL; breakpoint cluster region-Abelson point mutation T315I is resistant to ABL tyrosine kinase inhibitors. However, axitinib, a vascular endothelial growth factor receptor inhibitor, is effective agai...

Seiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, Juri Sakuta… in Journal of Hematology & Oncology (2015)

Article

Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells

The ABL kinase inhibitor imatinib is highly effective in treating most, but not all, patients with chronic myeloid leukemia (CML). This is because residual CML cells are generally present in the bone marrow mi...

Seiichi Okabe, Tetsuzo Tauchi, Seiichiro Katagiri… in Journal of Hematology & Oncology (2014)

Article

Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line

Nilotinib is approved for treatment of newly diagnosed chronic myeloid leukemia (CML) and it is shown superiority over imatinib in first-line treatment for patients of CML. In this study, we established a nilo...

Seiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka… in Journal of Hematology & Oncology (2011)

Article

Spontaneous Regression of Pulmonary Infiltration of Adult T-Cell Leukemia/Lymphoma

Vishant Jankipersadsing, Tetsuzo Tauchi, Yuko Tanaka… in International Journal of Hematology (2007)